Appendix One

Proposal to fund continuous glucose monitors, insulin pumps and insulin pump consumables for people with type 1 diabetes – resolutions

Continuous glucose monitors

resolve to award Dual Supply Status to Abbott and NZMS for their brands of continuous glucose monitor (standalone) and Continuous glucose monitor (interoperable) from 1 October 2024 until 30 September 2028;

resolve to create a new TG3 named 'Continuous Glucose Monitor' in the Diabetes Management TG2, Alimentary Tract and Metabolism therapeutic group in Section B of the Pharmaceutical Schedule from 1 October 2024;

resolve to apply Stat dispensing to continuous glucose monitors TG3 in Section B of the Pharmaceutical Schedule from 1 October 2024;

Standalone

resolve to list Abbott and NZMS' brands of continuous glucose monitor (standalone) in the Alimentary Tract and Metabolism - Continuous Glucose Monitor Therapeutic Group in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand (supplier)	Pack size	Price and subsidy (ex-manufacturer, excluding GST)
Continuous glucose monitor (standalone)	Sensor (Freestyle Libre 2)	Freestyle Libre 2 (Abbott)	1	$ 92.83
Continuous glucose monitor (standalone)	Sensor (Dexcom ONE+)	Dexcom ONE+ (NZMS)	1	$ 81.00

resolve to apply the following Special Authority criteria to Continuous glucose monitor (standalone) chemical in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

> Special Authority for Subsidy
> **Initial application –** (type 1 diabetes) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:
> Any of the following:
> 1. The patient has type 1 diabetes; or
> 2. The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist as likely to benefit; or
> 3. The patient has Type 3c diabetes considered by the treating endocrinologist as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
> 4. The patient has atypical inherited forms of diabetes.
>
> **Renewal** – (type 1 diabetes) from any relevant practitioner. Approvals valid for 2 years where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

resolve to apply the following restriction to Continuous glucose monitor (standalone) in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

a) Only on a prescription

resolve to apply the following rules to continuous glucose monitor sensors (standalone) sensor (Freestyle Libre 2) in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

a) Maximum of 29 dev will be funded per year.
b) Maximum of 6 dev per prescription

resolve to apply the following rules to continuous glucose monitor sensors (standalone) sensor (Dexcom ONE+) in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

a) Maximum of 40 dev will be funded per year.
b) Maximum of 9 dev per prescription

resolve to list on 1 October 2024 and delist on 1 January 2025 in the Various Therapeutic Group of Section B of the Pharmaceutical Schedule the following brand switch fee:

Chemical and presentation	Brand	Pack Size	Subsidy and price (ex-man., ex. GST)
Pharmacy Services, Brand switch fee (BSF)	BSF Continuous glucose monitor (standalone)	1 fee	$4.50
May only be claimed once per patient			

resolve to add a note to the following chemical name as listed in Section B of the Pharmaceutical Schedule from 1 October 2024 until 31 December 2024 as follows (changes in bold):

CONTINUOUS GLUCOSE MONITORS (STANDALONE) - **Brand Switch Fee payable**

Continuous glucose monitor (standalone) sensor	$ 92.83	1	√ **Freestyle Libre 2**
Continuous glucose monitor (standalone) sensor	$ 81.00	1	√ **Dexcom ONE+**

Interoperable

resolve to list NZMS' brands of Continuous glucose monitor (interoperable) in the Alimentary Tract and Metabolism - Continuous Glucose Monitor Therapeutic Group in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand	Pack size	Price and subsidy (ex-manufacturer, excluding GST)
Continuous glucose monitor (interoperable)	Sensor (9) and transmitter (Dexcom G6)	Dexcom G6	1 OP	$ 990.00
Continuous glucose monitor (interoperable)	Sensor (Dexcom G7)	Dexcom G7	1	$ 110.00

resolve to list Abbott's brand of Continuous glucose monitor (interoperable) in the Alimentary Tract and Metabolism - Continuous Glucose Monitor Therapeutic Group in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand	Pack size	Price and subsidy (ex-manufacturer, excluding GST)
Continuous glucose monitor (interoperable)	Sensor (Freestyle Libre 3 Plus)	Freestyle Libre 3 Plus	1	$99.46

resolve to apply the following Special Authority criteria to Continuous glucose monitor (interoperable) chemical in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Special Authority for Subsidy
Initial application - (type 1 diabetes) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:
Both:

1. Any of the following:
   1.1. The patient has type 1 diabetes; or
   1.2. The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist as likely to benefit; or
   1.3. The patient has Type 3c diabetes considered by the treating endocrinologist as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
   1.4. The patient has atypical inherited forms of diabetes; and
2. In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system.

Renewal – (type 1 diabetes) from any relevant practitioner. Approvals valid for 2 years where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

resolve to apply the following restrictions to Continuous glucose monitor (interoperable) in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

a) Only on a prescription

resolve to apply the following rules to funded continuous glucose monitor sensors (interoperable) in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows (rules in bold):

CONTINUOUS GLUCOSE MONITOR (INTEROPERABLE)
Sensor (Freestyle Libre 3 Plus)

a) **Maximum of 28 dev will be funded per year.**
b) **Maximum of 6 dev per prescription.**

CONTINUOUS GLUCOSE MONITOR (INTEROPERABLE)
Sensor (9) and transmitter (Dexcom G6)

a) **Maximum of 5 dev will be funded per year.**
b) **Maximum of 1 dev per prescription.**

Sensor (Dexcom G7)

a) **Maximum of 40 dev will be funded per year.**
b) **Maximum of 9 dev per prescription.**

note that confidential rebates would apply to Dexcom G6, Dexcom G7, Dexcom ONE+, Freestyle Libre 2, and Freestyle Libre 3 Plus that would reduce their net price.

resolve to list on 1 October 2024 and delist on 1 January 2025 in the Alimentary Tract and Metabolism Therapeutic Group of Section B of the Pharmaceutical Schedule the following brand switch fee:

Chemical and presentation	Brand	Pack Size	Subsidy and price (ex-man., ex. GST)
Pharmacy Services, Brand switch fee (BSF)	BSF Continuous glucose monitor (interoperable)	1 fee	$4.50
May only be claimed once per patient			

resolve to add a note to the following chemical name as listed in Section B of the Pharmaceutical Schedule from 1 October 2024 until 31 December 2024 as follows (changes in bold):

CONTINUOUS GLUCOSE MONITORS (INTEROPERABLE) - **Brand Switch Fee payable**

Continuous glucose monitor (interoperable)	$ 990.00	1 OP	√ **Dexcom G6**
Continuous glucose monitor (interoperable)	$ 110.00	1	√ **Dexcom G7**
Continuous glucose monitor (interoperable)	$99.46	1	√ **Freestyle Libre 3 Plus**

note that the provisional agreements for the Abbott and NZMS brands of continuous glucose monitor (standalone) and Continuous glucose monitor (interoperable) confer Dual Supply Status from 1 October 2024 until 30 September 2028 and this would not be explicitly reflected in the Pharmaceutical Schedule.

Insulin pumps

resolve to award Dual Supply Status to NZMS and Pharmaco for their brands of insulin pump with algorithm from 1 January 2025 until 30 September 2028.

resolve to create a new chemical 'Insulin Pump with Algorithm' under the Insulin Pump TG3, Diabetes Management TG2, Alimentary Tract and Metabolism therapeutic group in Section B of the Pharmaceutical Schedule from 1 October 2024;

resolve to move the following formulation and brand from 'Insulin Pump' to 'Insulin Pump with Algorithm' chemical in the Alimentary Tract and Metabolism Therapeutic Group in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

INSULIN PUMP WITH ALGORITHM	
Min basal rate 0.1 U/h	Tandem t:slim X2 with Basal-IQ

resolve to amend the price and subsidy for NZMS' brand of Insulin pump with algorithm in the Alimentary Tract and Metabolism Therapeutic Group, Insulin Pump with Algorithm chemical in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand	Pack size	Current price and subsidy	Proposed price and subsidy
Insulin pump with algorithm	Min basal rate 0.1 U/h	Tandem t:slim X2 with Basal-IQ	1	$4,500.00	$7,653.00

resolve to list NZMS' brand of Insulin pump with algorithm, in the Alimentary Tract and Metabolism Therapeutic Group, in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand	Pack size	Price and subsidy
Insulin pump with algorithm	Min basal rate 0.1 U/h	Tandem t:slim X2 with Control-IQ	1	$7,653.00

resolve to list Pharmaco's brand of insulin pump with algorithm in the Alimentary Tract and Metabolism Therapeutic Group, in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand	Pack size	Price and subsidy
Insulin pump with algorithm	Min basal rate 0.02 U/h	mylife YpsoPump with CamAPS FX	1	$8,970.00

resolve to apply the following Special Authority criteria to Insulin Pump with algorithm chemical in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Special Authority for Subsidy

Initial application – (type 1 diabetes) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:
All of the following:

1. Any of the following:
    1.1. The patient has type 1 diabetes; or
    1.2. The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist as likely to benefit; or
    1.3. The patient has Type 3c diabetes considered by the treating endocrinologist as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or
    1.4. The patient has atypical inherited forms of diabetes; and
2. Patient has been evaluated by a diabetes multidisciplinary team for their suitability for insulin pump therapy; and
3. In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system

Renewal – (type 1 diabetes) from any relevant practitioner. Approvals valid for 6 months where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

resolve to apply the Special Authority lapse period of 6 years for the initial and renewal criteria for Insulin Pump with Algorithm as listed in Section B of the Pharmaceutical Schedule from 1 October 2024.

resolve to apply the following restrictions to the chemical Insulin pump with algorithm in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

a) Only on a prescription
b) Maximum of 1 dev per prescription
c) Maximum of 1 insulin pump with algorithm each four year period

resolve to delist InterMed's brand of insulin pump (MiniMed 770G) from the Alimentary Tract and Metabolism Therapeutic Group in Section B of the Pharmaceutical Schedule on 1 January 2025 as follows:

Chemical and presentation	Brand
Insulin pump min basal rate 0.025 U/h	MiniMed 770G

note that no changes would be made to the chemical name for Insulin pump – min basal rate 0.025 U/h, MiniMed 770G brand.

note there are no proposed changes to the Special Authority criteria to SA1603 in Section B of the Pharmaceutical Schedule.

note that Insulin pump – Min basal rate 0.025 U/h MiniMed 770G would not be subject to the new Special Authority criteria and would remain subject to SA1603 until 31 December 2024.

note that confidential rebates would apply to Tandem t:slim X2 with Basal-IQ, Tandem t:slim X2 with Control-IQ and mylife YpsoPump with CamAPS FX that would reduce their net prices.

note that the provisional agreements for the NZMS and Pharmaco brands of insulin pump with algorithm confer Dual Supply Status from 1 January 2025 until 30 September 2028 and this would not be explicitly reflected in the Pharmaceutical Schedule.

Insulin pump consumables

resolve to award Dual Supply Status to NZMS and Pharmaco for their brands of insulin pump consumables from 1 October 2026 until 30 September 2028.

resolve to list NZMS' brand of Insulin pump infusion set (teflon cannula, variable insertion) in the Alimentary Tract and Metabolism – insulin pump consumables Therapeutic Group in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand	Pack size	Price and subsidy
Insulin pump infusion set (teflon cannula, variable insertion)	13 mm teflon cannula; variable insertion; 60 cm line x 10 with 10 needles	VariSoft	1 OP	$182.00

resolve to apply the following restrictions to the chemical Insulin pump infusion set (teflon cannula, variable insertion) in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

a) Only on a prescription
b) Maximum of 5 sets per prescription
c) Maximum of 19 infusion sets will be funded per year.

resolve to amend the price and subsidy for NZMS' brands of Insulin pump consumables in the Alimentary Tract and Metabolism Therapeutic Group in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand	Pack size	Current price and subsidy	Proposed price and subsidy
Insulin pump cartridge	Cartridge 300 U, t:lock x 10	Tandem Cartridge	1 OP	$50.00	$86.00
Insulin pump infusion set (teflon cannula, straight insertion with insertion device)	6 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles	Autosoft 90	1 OP	$140.00	$182.00
Insulin pump infusion set (teflon cannula, straight insertion with insertion device)	6 mm teflon cannula; straight insertion; 60 cm line x 10 with 10 needles	Autosoft 90	1 OP	$140.00	$182.00
Insulin pump infusion set (teflon cannula, straight insertion with insertion device)	9 mm teflon cannula; straight insertion; insertion device; 110 cm line x 10 with 10 needles	Autosoft 90	1 OP	$140.00	$182.00
Insulin pump infusion set (teflon cannula, straight insertion with insertion device)	9 mm teflon cannula; angle insertion; insertion device; 60 cm line x 10 with 10 needles	Autosoft 90	1 OP	$140.00	$182.00

Insulin pump infusion set (teflon cannula, angle insertion with insertion device)	13 mm teflon cannula; angle insertion; insertion device; 110 cm line x 10 with 10 needles	Autosoft 30	1 OP	$140.00	$182.00
Insulin pump infusion set (teflon cannula, angle insertion with insertion device)	13 mm teflon cannula; angle insertion; insertion device; 60 cm line x 10 with 10 needles	Autosoft 30	1 OP	$140.00	$182.00
Insulin pump infusion set (steel cannula, straight insertion)	6 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles	TruSteel	1 OP	$130.00	$182.00
Insulin pump infusion set (steel cannula, straight insertion)	6 mm steel cannula; straight insertion; 80 cm line x 10 with 10 needles	TruSteel	1 OP	$130.00	$182.00
Insulin pump infusion set (steel cannula, straight insertion)	8 mm steel cannula; straight insertion; 60 cm line x 10 with 10 needles	TruSteel	1 OP	$130.00	$182.00
Insulin pump infusion set (steel cannula, straight insertion)	8 mm steel cannula; straight insertion; 80 cm line x 10 with 10 needles	TruSteel	1 OP	$130.00	$182.00

resolve to list Pharmaco's brands of insulin pump consumables in the Alimentary Tract and Metabolism Therapeutic Group in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

Chemical	Formulation	Brand	Pack size	Price and subsidy
Insulin pump reservoir	10 x 1.6 ml glass reservoir for YpsoPump	mylife YpsoPump Reservoir	1 OP	$50.00
Insulin pump infusion set (steel cannula, straight insertion)	5.5 mm steel cannula; straight insertion; 45 cm line x 10 with 10 needles	mylife Orbit micro	1 OP	$136.00
Insulin pump infusion set (steel cannula, straight insertion)	5.5 mm steel needle; straight insertion; 60 cm line x 10 with 10 needles	mylife Orbit micro	1 OP	$136.00
Insulin pump infusion set (steel cannula, straight insertion)	5.5 mm steel needle; straight insertion; 80 cm line x 10 with 10 needles	mylife Orbit micro	1 OP	$136.00
Insulin pump infusion set (steel cannula, straight insertion)	8.5 mm steel needle; straight insertion; 60 cm line x 10 with 10 needles	mylife Orbit micro	1 OP	$136.00

Insulin pump infusion set (steel cannula, straight insertion)	8.5 mm steel needle; straight insertion; 80 cm line x 10 with 10 needles	mylife Orbit micro	1 OP	$136.00
Insulin pump infusion set (teflon cannula, flexible insertion with insertion device)	6 mm teflon cannula; flexible insertion; insertion device; 46 cm line x 10 with 10 needles	mylife Inset soft	1 OP	$157.00
Insulin pump infusion set (teflon cannula, flexible insertion with insertion device)	6 mm teflon cannula; flexible insertion; insertion device; 60 cm line with integrated inserter x 10 with 10 needles	mylife Inset soft	1 OP	$157.00
Insulin pump infusion set (teflon cannula, flexible insertion with insertion device)	6 mm teflon cannula; flexible insertion; insertion device; 80 cm line x 10 with 10 needles	mylife Inset soft	1 OP	$157.00
Insulin pump infusion set (teflon cannula, flexible insertion with insertion device)	9 mm teflon cannula; flexible insertion; insertion device; 60 cm line x 10 with 10 needles	mylife Inset soft	1 OP	$157.00
Insulin pump infusion set (teflon cannula, flexible insertion with insertion device)	9 mm teflon cannula; flexible insertion; insertion device; 80 cm line x 10 with 10 needles	mylife Inset soft	1 OP	$157.00

resolve to apply the following restrictions to the chemical Insulin pump infusion set (teflon cannula, flexible insertion with insertion device) in Section B of the Pharmaceutical Schedule from 1 October 2024 as follows:

a) Only on a prescription
b) Maximum of 5 sets per prescription
c) Maximum of 19 infusion sets will be funded per year.

resolve to amend the Special Authority criteria for Insulin Pump Consumables (TG3) in Section B of the Pharmaceutical Schedule with the following from 1 October 2024 (changes in bold and strikethrough):

Initial applications – (type 1 diabetes) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:
All of the following:

1. **Any of the following:**
   - **1.1. The patient has type 1 diabetes; or**
   - **1.2. The patient has permanent neonatal diabetes or specific monogenic diabetes subtypes with insulin deficiency, considered by the treating endocrinologist as likely to benefit; or**
   - **1.3. The patient has Type 3c diabetes considered by the treating endocrinologist as likely to benefit (Type 3c diabetes includes insulin deficiency due to pancreatectomy, insulin deficiency secondary to cystic fibrosis or pancreatitis); or**
   - **1.4. The patient has atypical inherited forms of diabetes; and**
2. **Patient has been evaluated by a diabetes multidisciplinary team for their suitability for insulin pump therapy; and**
3. **In the opinion of the treating relevant practitioner the patient would benefit from an Automated Insulin Delivery (AID) system**

Renewal – (type 1 diabetes) from any relevant practitioner. Approvals valid for 2 years where the patient is continuing to derive benefit according to the treatment plan agreed at induction.

~~Initial application — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:~~
~~All of the following:~~
~~1 Patient has permanent neonatal diabetes; and~~
~~2 A MDI regimen trial is inappropriate; and~~
~~3 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and~~
~~4 Patient/Parent/Guardian has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and~~
~~5 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and~~
~~6 Either:~~
~~6.1 Applicant is a relevant specialist; or~~
~~6.2 Applicant is a nurse practitioner working within their vocational scope.~~

~~Renewal — (permanent neonatal diabetes) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:~~
~~All of the following:~~
~~1 Patient is continuing to derive benefit according to the treatment plan agreed at induction; and~~
~~2 Patient remains fully compliant and transition to MDI is considered inappropriate by the treating physician; and~~
~~3 Either:~~
~~3.1 Applicant is a relevant specialist; or~~
~~3.2 Applicant is a nurse practitioner working within their vocational scope.~~

~~Initial application — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:~~
~~All of the following:~~
~~1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and~~
~~2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an appropriate health professional); and~~
~~3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and~~
~~4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and~~
~~5 Has had four severe unexplained hypoglycaemic episodes over a six month period (severe as defined as requiring the assistance of another person); and~~
~~6 Has an average HbA1c between the following range: equal to or greater than 53 mmol/mol and equal to or less than 90 mmol/mol; and~~
~~7 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and~~
~~8 Either:~~
~~8.1 Applicant is a relevant specialist; or~~
~~8.2 Applicant is a nurse practitioner working within their vocational scope.~~

~~Renewal — (severe unexplained hypoglycaemia) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:~~
~~All of the following:~~

1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of at least a 50% reduction from
baseline in hypoglycaemic events; and
2 HbA1c has not increased by more than 5 mmol/mol from baseline; and
3 Either:

- 3.1 Applicant is a relevant specialist; or
- 3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 9 months for applications meeting the following criteria:
All of the following:
1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
2 Has undertaken carbohydrate counting education (either a carbohydrate counting course or direct education from an
appropriate health professional); and
3 Applicant is part of a multidisciplinary team experienced in the management of type 1 diabetes care; and
4 Has adhered to an intensive MDI regimen using analogue insulins for at least six months; and
5 Has unpredictable and significant variability in blood glucose including significant hypoglycaemia affecting the ability to
reduce HbA1; and
6 In the opinion of the treating clinician, HbA1c could be reduced by at least 10 mmol/mol using insulin pump treatment; and
7 Has typical HbA1c results between the following range: equal to or greater than 65 mmol/mol and equal to or less than
90 mmol/mol; and
8 Has been evaluated by the multidisciplinary team for their suitability for insulin pump therapy; and
9 Either:

- 9.1 Applicant is a relevant specialist; or
- 9.2 Applicant is a nurse practitioner working within their vocational scope.

Renewal — (HbA1c) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:
All of the following:
1 Patient is continuing to derive benefit according to the treatment plan agreed at induction of achieving and maintaining a
reduction in HbA1c from baseline of 10 mmol/mol; and
2 The number of severe unexplained recurrent hypoglycaemic episodes has not increased from baseline; and
3 Either:

- 3.1 Applicant is a relevant specialist; or
- 3.2 Applicant is a nurse practitioner working within their vocational scope.

Initial application — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:
All of the following:
1 Patient has type 1 diabetes or has undergone a pancreatectomy or has cystic fibrosis-related diabetes; and
2 Was already on pump treatment prior to 1 September 2012 and had been evaluated by the multidisciplinary team for their
suitability for insulin pump therapy at the time of initiating that pump treatment and continues to benefit from pump
treatment; and
3 The patient has adhered to an intensive MDI regimen using analogue insulins for at least six months prior to initiating
pump therapy; and
4 The patient is continuing to derive benefit from pump therapy; and
5 The patient had achieved and is maintaining a HbA1c of equal to or less than 80 mmol/mol on pump therapy; and

~~6 The patient has had no increase in severe unexplained hypoglycaemic episodes from baseline; and~~
~~7 The patient's HbA1c has not deteriorated more than 5 mmol/mol from baseline; and~~
~~8 Either:~~
~~8.1 Applicant is a relevant specialist; or~~
~~8.2 Applicant is a nurse practitioner working within their vocational scope.~~

~~Renewal — (Previous use before 1 September 2012) only from a relevant specialist or nurse practitioner. Approvals valid for 2 years for applications meeting the following criteria:~~
~~All of the following:~~
~~1 The patient is continuing to derive benefit according to the treatment plan and has maintained a HbA1c of equal to or less than 80 mmol/mol; and~~
~~2 The patient's HbA1c has not deteriorated more than 5 mmol/mol from initial application; and~~
~~3 The patient has not had an increase in severe unexplained hypoglycaemic episodes from baseline; and~~
~~4 Either:~~
~~4.1 Applicant is a relevant specialist; or~~
~~4.2 Applicant is a nurse practitioner working within their vocational scope~~.

note that the new Special Authority criteria applies to all brands and presentations of insulin pump consumables.

resolve to apply Stat dispensing to insulin pump consumables TG3 in Section B of the Pharmaceutical Schedule from 1 October 2024;

resolve to amend the quantity restrictions to the following insulin pump consumables in Section B of the Pharmaceutical Schedule from 1 October 2024 (deletions in strikethrough and additions in bold):

INSULIN PUMP CARTRIDGE
a) Maximum of ~~3~~ **5** packs per prescription
b) Only on a prescription
c) Maximum of ~~13~~ **19** packs of consumables would be funded per year.

INSULIN PUMP INFUSION SET (STEEL CANNULA)
a) Maximum of ~~3~~ **5** packs per prescription
b) Only on a prescription
c) Maximum of ~~13~~ **19** packs of consumables would be funded per year.

INSULIN PUMP INFUSION SET (STEEL CANNULA, STRAIGHT INSERTION)
a) Maximum of ~~3~~ **5** packs per prescription
b) Only on a prescription
c) Maximum of ~~13~~ **19** packs of consumables would be funded per year.

INSULIN PUMP INFUSION SET (TEFLON CANNULA)
a) Maximum of ~~3~~ **5** packs per prescription
b) Only on a prescription
c) Maximum of ~~13~~ **19** packs of consumables would be funded per year.

INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE INSERTION WITH INSERTION DEVICE)
a) Maximum of ~~3~~ **5** packs per prescription

b) Only on a prescription
c) Maximum of ~~13~~ **19** packs of consumables would be funded per year.

INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGHT INSERTION WITH INSERTION DEVICE)
a) Maximum of ~~3~~ **5** packs per prescription
b) Only on a prescription
c) Maximum of ~~13~~ **19** packs of consumables would be funded per year.

INSULIN PUMP RESERVOIR
a) Maximum of ~~3~~ **9** packs per prescription
b) Only on a prescription
c) Maximum of ~~13~~ **36** packs of consumables would be funded per year.

note that confidential rebates would apply to NZMS' brands of insulin pump consumables that would reduce the net prices and that there is no confidential rebate for Pharmaco's brands of insulin pump consumables.

note that the provisional agreements for the NZMS and Pharmaco brands of insulin pump consumables confer Dual Supply Status from 1 October 2026 until 30 September 2028 and this would not be explicitly reflected in the Pharmaceutical Schedule.

resolve to delist InterMed's brands of insulin pump consumables from the Alimentary Tract and Metabolism Therapeutic Group in Section B of the Pharmaceutical Schedule on 1 October 2026 as follows:

Chemical	Formulation	Brand	Pharmacode
Insulin pump infusion set (steel cannula)	6 mm steel needle; 60 cm tubing x 10	MiniMed Sure-T MMT-864A	2591685
Insulin pump infusion set (steel cannula)	6 mm steel needle; 80 cm tubing x 10	MiniMed Sure-T MMT-866A	2591693
Insulin pump infusion set (steel cannula)	8 mm steel needle; 60 cm tubing x 10	MiniMed Sure-T MMT-874A	2591707
Insulin pump infusion set (steel cannula)	8 mm steel needle; 80 cm tubing x 10	MiniMed Sure-T MMT-876A	2591715
Insulin pump infusion set (teflon cannula)	13 mm teflon needle, 60 cm tubing x 10	MiniMed Silhouette MMT-381A	2591561
Insulin pump infusion set (teflon cannula)	17 mm teflon needle, 110 cm tubing x 10	MiniMed Silhouette MMT-377A	2591545
Insulin pump infusion set (teflon cannula)	17 mm teflon needle, 60 cm tubing x 10	MiniMed Silhouette MMT-378A	2591553
Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 110 cm tubing x 10	MiniMed Quick-Set MMT-398A	2591669

Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 45 cm blue tubing x 10	MiniMed Mio MMT-941A	2591782
Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 45 cm pink tubing x 10	MiniMed Mio MMT-921A	2591758
Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 60 cm blue tubing x 10	MiniMed Mio MMT-943A	2591790
Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 60 cm pink tubing x 10	MiniMed Mio MMT-923A	2591766
Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 60 cm tubing x 10	MiniMed Quick-Set MMT-399A	2591677
Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 80 cm blue tubing x 10	MiniMed Mio MMT-945A	2591804
Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 80 cm clear tubing x 10	MiniMed Mio MMT-965A	2591812
Insulin pump infusion set (teflon cannula)	6 mm teflon needle, 80 cm pink tubing x 10	MiniMed Mio MMT-925A	2591774
Insulin pump infusion set (teflon cannula)	9 mm teflon needle, 110 cm tubing x 10	MiniMed Quick-Set MMT-396A	2591642
Insulin pump infusion set (teflon cannula)	9 mm teflon needle, 60 cm tubing x 10	MiniMed Quick-Set MMT-397A	2591650
Insulin pump infusion set (teflon cannula)	9 mm teflon needle, 80 cm clear tubing x 10	MiniMed Mio MMT-975A	2591820
Insulin pump reservoir	10 x luer lock conversion cartridges 1.8 ml for Paradigm pumps	ADR Cartridge 1.8	2423065
Insulin pump reservoir	Cartridge for 7 series pump; 3.0ml x 10	MiniMed 3.0 Reservoir MMT-332A	2430371